Denise Loring to discuss trends in pharmaceutical patent cases at ACI conference

Denise Loring, a partner in Ropes & Gray's IP Group, will be a featured speaker at the American Conference Institute's ninth annual conference, "Maximizing Pharmaceutical Patent Life Cycles," to be held October 15 - 16 in New York. Loring will serve on a panel that will discuss the topic of identifying judicial trends in pharmaceutical patent cases. Her panel, which will convene at 3:45 pm on October 15, will address the following topics:

• The Four Horsemen of the Apocalypse: Delineating the thundering change for patent life cycles triggered by Medimmune, In re Seagate, eBay, KSR and their progeny
   
• Deconstructing the effect, value, and challenges of the covenant not to sue in a post-MedImmune world
  
  What types of covenants have the courts embraced?
  
  What language will trigger rejections by the courts?
  
  Factoring the risk in pursuing a covenant not to sue

• Defining the influence of In re Seagate on the concept of ‘reckless disregard’
  
  How does In re Seagate change the need to get a patent opinion?
  
  Scrutinizing the courts’ opinions on the issue of willful infringement in pharma patent cases to project their bearing on present cases

• Factoring the eBay decision concerning ‘compulsory licensing’ into your life cycle analysis
  
  Forming a strategy to argue for or defend against an injunction
  
  Examining the different rationales behind preliminary and permanent injunctions
  
  Investigating the decreasing ability to get a preliminary injunction in the initial phase of a patent trial

• Adjusting your pharmaceutical patent life cycle strategy to consider the impact of KSR on the obviousness standard
  
  Does KSR eliminate secondary patent protection?

• Analyzing court opinions on inequitable conduct to further examine the risks in pharma patent challenges
   
• Determining the latest judicial trends and their consequent impact on a patent life cycle strategy
  
  Forecasting the courts’ future trends in pharma patent cases
  
  What is the Roberts Court’s view of patent cases?